A: While there isn't a universally fixed 'maximum,' researchers typically aim for the minimum effective 5-Amino-1MQ dosage to minimize off-target effects
After day 21, degradation begins to accelerate, dropping to roughly 89.7% by day 30
Absence of Common Growth Hormone Side Effects: Because AOD-9604 does not bind to growth hormone receptors or elevate IGF-1, it avoids edema and fluid retention, joint pain and stiffness, carpal tunnel syndrome, glucose elevation and insulin resistance, increased cancer risk concerns from IGF-1 elevation, organ growth or acromegaly features with long-term use, and thyroid function suppression
Its fragment-based structure gives it a more focused research role for laboratories working on targeted signaling review, growth hormone-related pathway modeling, and controlled metabolic system analysis
The public docket (FDA-2025-N-6895) is open for written comments at regulations.gov